Hem › Steatotisk leversjukdom › Tennessee
Kliniska studier för Steatotisk leversjukdom i Tennessee
7 studier för Steatotisk leversjukdom söker deltagare vid platser i Tennessee.
Städer i Tennessee
Officiell studietext (engelska)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Cordova
- 89bio Clinical Study Site, Hermitage
- 89bio Clinical Study Site, Nashville
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 5 okt. 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Chattanooga
- 89bio Clinical Study Site, Cordova
- 89bio Clinical Study Site, Hermitage
- och 1 fler
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 5 okt. 2026 · NCT06318169A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Galen Medical Group - Galen Hepatology, Chattanooga
- Gastro One (Walnut Run Road), Cordova
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Clarksville
- Akero Clinical Study Site, Hermitage
- Akero Clinical Study Site, Nashville
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 21 sep. 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Chattanooga
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 17 sep. 2026 · NCT07221188A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Hermitage
RekryterarFas 2
Ålder 18 till 70 · Alla kön · Uppdaterad 3 aug. 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Chattanooga
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 27 juli 2026 · NCT07221227Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.